 Amy Keller
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catechin | 3 | 2022 | 24 | 2.210 |
Why?
| | Mitochondria | 9 | 2025 | 877 | 1.380 |
Why?
| | Vascular Diseases | 2 | 2022 | 241 | 1.170 |
Why?
| | Endothelium, Vascular | 4 | 2022 | 901 | 1.030 |
Why?
| | Mitochondria, Muscle | 3 | 2016 | 111 | 1.000 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2025 | 203 | 0.900 |
Why?
| | Rats, Wistar | 6 | 2025 | 441 | 0.850 |
Why?
| | Glucose | 4 | 2022 | 1003 | 0.800 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.750 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2016 | 182 | 0.720 |
Why?
| | Glucose Intolerance | 1 | 2022 | 142 | 0.710 |
Why?
| | Adipose Tissue | 1 | 2025 | 592 | 0.710 |
Why?
| | Rats | 10 | 2025 | 5500 | 0.640 |
Why?
| | Insulin | 5 | 2022 | 2326 | 0.640 |
Why?
| | Blood Vessels | 2 | 2018 | 187 | 0.630 |
Why?
| | Pterins | 1 | 2018 | 8 | 0.610 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2016 | 443 | 0.610 |
Why?
| | Homocysteine | 1 | 2019 | 152 | 0.600 |
Why?
| | Adaptation, Physiological | 4 | 2018 | 513 | 0.590 |
Why?
| | Momordica charantia | 3 | 2014 | 15 | 0.580 |
Why?
| | Cysteine | 1 | 2019 | 195 | 0.570 |
Why?
| | Immediate-Early Proteins | 1 | 2016 | 52 | 0.510 |
Why?
| | Electron Transport Complex IV | 1 | 2016 | 57 | 0.510 |
Why?
| | Menopause | 1 | 2019 | 297 | 0.500 |
Why?
| | Viral Envelope Proteins | 1 | 2016 | 81 | 0.490 |
Why?
| | Vasodilation | 4 | 2025 | 476 | 0.490 |
Why?
| | Adamantane | 1 | 2015 | 16 | 0.470 |
Why?
| | Saponins | 2 | 2011 | 8 | 0.470 |
Why?
| | Dipeptides | 1 | 2015 | 49 | 0.470 |
Why?
| | Oxidative Stress | 2 | 2020 | 1269 | 0.440 |
Why?
| | Insulin Resistance | 1 | 2022 | 1165 | 0.440 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2016 | 259 | 0.440 |
Why?
| | Cardiovascular Diseases | 3 | 2022 | 2004 | 0.430 |
Why?
| | Host-Pathogen Interactions | 1 | 2016 | 352 | 0.410 |
Why?
| | Motor Activity | 2 | 2015 | 676 | 0.410 |
Why?
| | Models, Biological | 1 | 2020 | 1722 | 0.410 |
Why?
| | Herpesvirus 3, Human | 1 | 2016 | 331 | 0.400 |
Why?
| | Aorta | 5 | 2018 | 411 | 0.390 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 49 | 0.370 |
Why?
| | Fibroblasts | 1 | 2016 | 948 | 0.360 |
Why?
| | Plant Extracts | 2 | 2011 | 199 | 0.340 |
Why?
| | Animals | 15 | 2025 | 35361 | 0.340 |
Why?
| | Insulin-Secreting Cells | 2 | 2011 | 367 | 0.330 |
Why?
| | Cell Respiration | 2 | 2020 | 98 | 0.320 |
Why?
| | Costus | 1 | 2008 | 1 | 0.310 |
Why?
| | Nitric Oxide | 3 | 2022 | 902 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2015 | 2441 | 0.290 |
Why?
| | Superoxides | 2 | 2020 | 201 | 0.280 |
Why?
| | Human Umbilical Vein Endothelial Cells | 2 | 2020 | 101 | 0.280 |
Why?
| | Postmenopause | 2 | 2019 | 351 | 0.270 |
Why?
| | Estradiol | 2 | 2019 | 494 | 0.250 |
Why?
| | Adipose Tissue, Brown | 1 | 2025 | 51 | 0.230 |
Why?
| | Physical Conditioning, Animal | 2 | 2018 | 229 | 0.220 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 207 | 0.210 |
Why?
| | Signal Transduction | 3 | 2022 | 4925 | 0.200 |
Why?
| | Triterpenes | 2 | 2014 | 20 | 0.200 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 2 | 2020 | 41 | 0.200 |
Why?
| | Overnutrition | 1 | 2022 | 30 | 0.190 |
Why?
| | Temperature | 1 | 2025 | 636 | 0.190 |
Why?
| | Lipids | 2 | 2022 | 625 | 0.190 |
Why?
| | Nitric Oxide Synthase | 1 | 2022 | 237 | 0.190 |
Why?
| | Transgender Persons | 1 | 2024 | 172 | 0.180 |
Why?
| | Blood Glucose | 3 | 2022 | 2097 | 0.180 |
Why?
| | Respiration | 1 | 2022 | 191 | 0.180 |
Why?
| | Housing | 1 | 2022 | 130 | 0.180 |
Why?
| | Testosterone | 1 | 2024 | 372 | 0.180 |
Why?
| | Glutathione | 1 | 2022 | 348 | 0.170 |
Why?
| | Antimycin A | 1 | 2020 | 13 | 0.170 |
Why?
| | Vasoconstriction | 2 | 2018 | 199 | 0.170 |
Why?
| | Electron Transport Complex I | 1 | 2020 | 39 | 0.170 |
Why?
| | Cell Line | 3 | 2016 | 2781 | 0.160 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 596 | 0.160 |
Why?
| | Sirtuin 3 | 1 | 2020 | 58 | 0.160 |
Why?
| | Male | 10 | 2025 | 63682 | 0.150 |
Why?
| | Heart Diseases | 1 | 2022 | 350 | 0.150 |
Why?
| | Carbohydrates | 1 | 2018 | 64 | 0.150 |
Why?
| | Protein Kinases | 1 | 2020 | 318 | 0.150 |
Why?
| | Brachial Artery | 1 | 2019 | 192 | 0.140 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 92 | 0.140 |
Why?
| | Muscle Proteins | 1 | 2019 | 220 | 0.140 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 356 | 0.140 |
Why?
| | Carotid Arteries | 1 | 2018 | 196 | 0.130 |
Why?
| | Glycosides | 2 | 2014 | 37 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1033 | 0.130 |
Why?
| | Nutritional Status | 1 | 2019 | 328 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 365 | 0.130 |
Why?
| | Plants, Medicinal | 2 | 2014 | 22 | 0.120 |
Why?
| | Diabetes Mellitus | 2 | 2014 | 1001 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 573 | 0.120 |
Why?
| | Cytoplasm | 1 | 2016 | 263 | 0.120 |
Why?
| | Genes, Reporter | 1 | 2016 | 267 | 0.120 |
Why?
| | Mitochondrial Proteins | 2 | 2015 | 248 | 0.120 |
Why?
| | Organelle Biogenesis | 1 | 2015 | 15 | 0.120 |
Why?
| | Fruit | 2 | 2014 | 131 | 0.120 |
Why?
| | Green Fluorescent Proteins | 1 | 2016 | 385 | 0.110 |
Why?
| | Cell Death | 1 | 2016 | 354 | 0.110 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2015 | 45 | 0.110 |
Why?
| | Hypoglycemic Agents | 2 | 2014 | 1220 | 0.110 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2015 | 112 | 0.110 |
Why?
| | Disease Models, Animal | 2 | 2015 | 4063 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 1 | 2016 | 643 | 0.110 |
Why?
| | Cell Nucleus | 1 | 2016 | 582 | 0.100 |
Why?
| | Mitochondrial Dynamics | 1 | 2013 | 37 | 0.100 |
Why?
| | Fetus | 1 | 2016 | 773 | 0.090 |
Why?
| | Phytotherapy | 1 | 2011 | 79 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 744 | 0.090 |
Why?
| | Diet | 1 | 2019 | 1213 | 0.090 |
Why?
| | Seeds | 1 | 2011 | 84 | 0.090 |
Why?
| | Obesity | 3 | 2022 | 2883 | 0.090 |
Why?
| | Software | 1 | 2015 | 608 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2548 | 0.090 |
Why?
| | Protein Binding | 1 | 2016 | 2121 | 0.080 |
Why?
| | Female | 5 | 2025 | 68777 | 0.080 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 339 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2019 | 1614 | 0.080 |
Why?
| | Dominican Republic | 1 | 2008 | 23 | 0.080 |
Why?
| | Medicine, Traditional | 1 | 2008 | 22 | 0.080 |
Why?
| | Injections, Intraperitoneal | 1 | 2008 | 111 | 0.080 |
Why?
| | Mice | 4 | 2022 | 16937 | 0.070 |
Why?
| | Humans | 9 | 2024 | 129652 | 0.070 |
Why?
| | Plant Leaves | 1 | 2008 | 139 | 0.070 |
Why?
| | PPAR gamma | 2 | 2022 | 183 | 0.070 |
Why?
| | Hyperglycemia | 1 | 2008 | 328 | 0.060 |
Why?
| | Weight Gain | 1 | 2008 | 510 | 0.060 |
Why?
| | Hypertension | 1 | 2012 | 1242 | 0.050 |
Why?
| | Puberty | 1 | 2024 | 143 | 0.050 |
Why?
| | Lung | 1 | 2016 | 3931 | 0.050 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 2 | 2014 | 141 | 0.050 |
Why?
| | Exercise | 1 | 2014 | 1925 | 0.050 |
Why?
| | Young Adult | 1 | 2019 | 12427 | 0.050 |
Why?
| | Adult Children | 1 | 2022 | 23 | 0.050 |
Why?
| | Carnitine | 1 | 2022 | 76 | 0.050 |
Why?
| | Fetal Heart | 1 | 2022 | 55 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2024 | 672 | 0.050 |
Why?
| | Cardiomegaly | 1 | 2022 | 172 | 0.040 |
Why?
| | Disease Progression | 1 | 2008 | 2635 | 0.040 |
Why?
| | Middle Aged | 2 | 2019 | 31155 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2015 | 10230 | 0.040 |
Why?
| | Aged | 1 | 2019 | 22104 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2008 | 5440 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 133 | 0.040 |
Why?
| | Mitochondria, Heart | 1 | 2018 | 94 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2013 | 2406 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2717 | 0.030 |
Why?
| | Adult | 1 | 2019 | 35577 | 0.030 |
Why?
| | Exercise Tolerance | 1 | 2018 | 273 | 0.030 |
Why?
| | Sterols | 1 | 2014 | 18 | 0.030 |
Why?
| | Caco-2 Cells | 1 | 2014 | 75 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2018 | 692 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2015 | 400 | 0.030 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2013 | 9 | 0.030 |
Why?
| | Electron Transport Chain Complex Proteins | 1 | 2013 | 20 | 0.030 |
Why?
| | Biological Transport | 1 | 2014 | 401 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2013 | 48 | 0.030 |
Why?
| | Vascular Stiffness | 1 | 2018 | 467 | 0.030 |
Why?
| | Uncoupling Protein 3 | 1 | 2012 | 8 | 0.030 |
Why?
| | Rats, Mutant Strains | 1 | 2012 | 24 | 0.030 |
Why?
| | Heterozygote | 1 | 2013 | 272 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2014 | 582 | 0.020 |
Why?
| | Ion Channels | 1 | 2012 | 133 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 2012 | 187 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 379 | 0.020 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 191 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 716 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 342 | 0.020 |
Why?
| | Autophagy | 1 | 2013 | 268 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6402 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2012 | 388 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 257 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6556 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1472 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3973 | 0.020 |
Why?
| | Adolescent | 1 | 2024 | 20394 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 2017 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1651 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 14518 | 0.010 |
Why?
|
|
Keller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|